Raymond James & Associates’s Achillion Pharmaceuticals ACHN Stock Holding History

Raymond James & Associates’s Portfolio ACHN Stock Details ACHN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-20,300	Closed	-$3K	–	3798
2019 Q3	$3K	Buy	+20,300	New	+$78.3K	﹤0.01%	3591
2016 Q3	–	Sell	-41,800	Closed	-$8K	–	3336
2016 Q2	$8K	Buy	+41,800	New	+$359K	﹤0.01%	2975

Raymond James & Associates's ACHN Position: Q1 2020 in Review

Raymond James & Associates sold out of Achillion Pharmaceuticals (ACHN) in Q1 2020, closing a stake of 27,216 shares — an estimated $164K sold.

Raymond James & Associates first reported a position in ACHN in Q1 2014 and held it in 24 quarters. The position peaked at $1.28M in Q4 2015. 0 funds tracked by Wall St. Rank hold ACHN as of Q1 2020.

Raymond James & Associates reported no remaining Achillion Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
Raymond James & Associates sold 27,216 Achillion Pharmaceuticals shares in Q1 2020, an estimated $164K.
Raymond James & Associates first reported a position in Achillion Pharmaceuticals in Q1 2014 and held it in 24 quarters.
Raymond James & Associates's Achillion Pharmaceuticals position peaked at $1.28M in Q4 2015.
0 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q1 2020.

Based on Raymond James & Associates's 13F filing for Q1 2020, filed 21 Apr 2020.